What are the recommended initial dosing, monitoring, and follow‑up for antithyroid drugs (methimazole and propylthiouracil) in the treatment of hyperthyroidism?

Antithyroid Medications: Initial Dosing, Monitoring, and Follow-Up

Methimazole should be your first-line antithyroid drug at 10-20 mg daily for most patients, with propylthiouracil reserved only for first-trimester pregnancy, thyroid storm, or methimazole intolerance. 1

Drug Selection

Methimazole is superior to propylthiouracil in virtually all clinical scenarios except three specific situations 1:

• First trimester of pregnancy (use PTU due to MMI teratogenicity risk including choanal/esophageal atresia and aplasia cutis)
• Thyroid storm
• Minor reactions to methimazole in patients refusing radioiodine or surgery

The evidence strongly favors methimazole because it has once-daily dosing, lower rates of major adverse effects, and reduced hepatotoxicity compared to PTU 1. PTU carries an FDA black box warning for potentially fatal hepatic necrosis requiring liver transplantation 1.

Initial Dosing

Methimazole 1, 2:

• Mild hyperthyroidism: 10-15 mg once daily
• Moderate hyperthyroidism: 20-30 mg once daily
• Severe hyperthyroidism: 30-40 mg once daily (up to 60 mg for very severe cases)

Propylthiouracil (when indicated) 1, 3:

• Standard initial dose: 50-150 mg three times daily (150-450 mg total daily)
• Severe hyperthyroidism: Up to 600-900 mg daily in divided doses
• Pregnancy: Keep doses as low as possible (150-200 mg/day) 4

Important dosing note: The potency ratio is approximately 20-30:1 (PTU:MMI), meaning 300 mg PTU equals roughly 10-15 mg MMI 1.

Pre-Treatment Baseline Testing

Before initiating therapy, obtain 1:

• Complete blood count with differential (baseline absolute neutrophil count)
• Liver function tests including bilirubin and transaminases (ALT, AST)

Contraindications to starting therapy 1:

• Absolute neutrophil count <500/mm³
• Liver transaminases >5 times upper limit of normal

Patient Education (Critical Safety Component)

Before starting and at every visit, instruct patients to immediately stop medication and contact you if they develop 1:

• Fever or pharyngitis (agranulocytosis warning)
• Jaundice, dark urine, or acholic stools (hepatotoxicity)
• Pruritic rash
• Arthralgias or abdominal pain
• Severe fatigue or nausea

Document this counseling in writing—provide both verbal and written information 1.

Monitoring Schedule

Thyroid Function Testing:

• Initial phase: Check free T4 (and TSH if not suppressed) every 2-4 weeks until euthyroid
• Maintenance phase: Every 4-8 weeks once stable
• Goal: Normalize free T4 first; TSH may remain suppressed for 1+ months after hyperthyroidism resolves 1

Routine Laboratory Monitoring:

Do not perform routine CBC or LFT monitoring in asymptomatic patients—most serious adverse events (agranulocytosis, hepatotoxicity) occur suddenly and are not prevented by routine monitoring 1. Instead, rely on symptom-based surveillance with immediate evaluation if warning symptoms develop.

Dose Titration

Methimazole:

• Once euthyroid (typically 4-8 weeks), reduce to maintenance dose of 5-10 mg daily 1
• Continue for 12-18 months total before considering discontinuation 4

Propylthiouracil:

• Reduce to maintenance dose of 50 mg 2-3 times daily once euthyroid 1

Avoid "block-and-replace" therapy (high-dose antithyroid drug plus levothyroxine)—this increases adverse effects without improving outcomes 1.

Special Populations

Pregnancy:

• First trimester: Use PTU exclusively (switch from MMI immediately upon positive pregnancy test) 1
• Second/third trimester: Switch to methimazole at beginning of second trimester 1
• Target: Keep free T4 at or slightly above upper limit of normal; TSH will remain suppressed 1
• Monitoring: Monthly thyroid function tests with dose adjustments 1
• Use lowest effective dose to avoid fetal hypothyroidism

Lactation:

• Methimazole is preferred over PTU due to hepatotoxicity risk 1

Pediatrics:

• Methimazole: 0.4 mg/kg/day divided into 3 doses initially; maintenance ~0.2 mg/kg/day 2
• Avoid PTU in children except rare circumstances due to hepatotoxicity risk 3

Common Pitfalls to Avoid

1. Don't use PTU as first-line except in the three specific scenarios above—hepatotoxicity risk is too high 1, 5

2. Don't start with excessive doses—agranulocytosis risk is dose-dependent; starting doses >20 mg MMI increase complications 5, 6

3. Don't rely on routine lab monitoring to catch agranulocytosis or hepatotoxicity—these occur suddenly; symptom surveillance is key 1

4. Don't use block-and-replace as initial strategy—higher adverse event rates without benefit 1

5. Don't forget to switch drugs in pregnancy—PTU first trimester only, then MMI 1

Adverse Event Profile

Methimazole 1, 7:

• Agranulocytosis (rare, dose-dependent, typically early in treatment)
• Cholestatic hepatotoxicity (less severe than PTU)
• Teratogenicity in first trimester

Propylthiouracil 1, 7:

• Fulminant hepatic necrosis (potentially fatal, FDA warning)
• ANCA-positive vasculitis (risk increases with duration)
• Agranulocytosis
• 2.4× higher odds of liver injury vs MMI 7
• 4× higher odds of elevated transaminases vs MMI 7